Dr. Tom Thompson - Pubmed


A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL. Cooke AL, Morris J, Melchior JT, Street SE, Jerome WG, Huang R, Herr AB, Smith LE, Segrest JP, Remaley AT, Shah AS, Thompson TB, Davidson WS. Journal of lipid research. 2018; 59(7):1244-1255. PMID: 29773713. PMCID: PMC6027914. (Pub Med)

New Insight Into Hyperemesis Gravidarum and a Potential Role for GDF15. Walker RG, Thompson TB. Endocrinology. 2018; 159(7):2698-2700. PMID: 29846562. (Pub Med)

Structure of the human myostatin precursor and determinants of growth factor latency. Cotton TR, Fischer G, Wang X, McCoy JC, Czepnik M, Thompson TB, Hyvönen M. EMBO J. Jan 12. pii: e97883. doi: 10.15252/embj.201797883. (Pub Med)

Molecular characterization of latent GDF8 reveals mechanisms of activation. Walker RG, McCoy JC, Czepnik M, Mills MJ, Hagg A, Walton KL, Cotton TR, Hyvönen M, Lee RT, Gregorevic P, Harrison CA, Thompson TB. Proceedings of the National Academy of Sciences of the United States of America. 2018; 155(5):E866-E875. PMID: 29348202. PMCID: 5798348.(Pub Med)


A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state.    Melchior JT, Walker RG, Cooke AL, Morris J, Castleberry M, Thompson TB, Jones MK, Song HD, Rye KA, Oda MN, Sorci-Thomas MG, Thomas MJ, Heinecke JW, Mei X, Atkinson D, Segrest JP, Lund-Katz S, Phillips MC, Davidson WS. Nature structural & molecular biology. 2017; (Pub Med)

Coordinated Proliferation and Differentiation of Human-Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells Depend on Bone Morphogenetic Protein Signaling Regulation by GREMLIN 2. Bylund JB, Trinh LT, Awgulewitsch CP, Paik DT, Jetter C, Jha R, Zhang J, Nolan K, Xu C, Thompson TB, Kamp TJ, Hatzopoulos AK. Stem cells and development. 2017; 26(9):678-693. (Pub Med)

Analysis and identification of the Grem2 heparin/heparan sulfate-binding motif.          Kattamuri C, Nolan K, Thompson TB. The Biochemical journal. 2017; 474(7):1093-1107. (Pub Med)

Structural basis for potency differences between GDF8 and GDF11.                                     Walker RG, Czepnik M, Goebel EJ, McCoy JC, Vujic A, Cho M, Oh J, Aykul S, Walton KL, Schang G, Bernard DJ, Hinck AP, Harrison CA, Martinez-Hackert E, Wagers AJ, Lee RT, Thompson TB. BMC biology. 2017; 15(1):19. (Pub Med)


MuSK as a BMP Co-Receptor
Yilmaz, A.; Kattamuri, C.; Ozdeslik, R.N.; Schmiedel, C.; Mentor, S.; Schori, C.; Oancea, E.; Thompson, T.B.; Fallon, J.R., MuSK is a BMP co-receptor that shapes BMP responses and calcium signaling in muscle cells. Sci Signal. 2016. 9(444):ra87. (Pub Med)

Structure of Gremlin-2:GDF5 Complex
Nolan, L.; Kattamuri, C.; Rankin, S.A.; Read, R.J.; Zorn, A.M.; Thompson, T.B., Structure of Gremlin-2 in Complex with GDF5 Gives Insight into DAN-Family-Mediated BMP Antagonism. Cell Rep. 2016 . 16(8):2077-86. (Pub Med)

BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction.
Sanders, L.N.; Showenhard, J.A.; Saleh, M.A.; Mukherjee, A.; Ryzhov, S.; McMaster, W.G. Jr; Nolan, K.; Gumina, R.J.; Thompson, T.B.; Magnuson, M.A.; Harrison, D.G.; Hatzopoulos, A.K., BMP Antagonist Gremlin 2 Limits Inflammation After Myocardial Infarction. Circ Res. 2016, 119(3)434-49. (Pub Med)

Structure of C-terminal Truncated Apolipoprotein A-I in Solution.
Melchior, J.T.; Walker, R.G.; Morris, J.; Jones, M.K.; Segrest, J.P.; Lima, D.B.; Carvalho, P.C.; Gozzo, F.C.; Castleberry, M.; Thompson, T.B.; Davidson, W.S., An Evaluation of the Crystal Structure of C-terminal Truncated Apolipoprotein A-I in Solution Reveals Structural Dynamics Related to Lipid Binding. J Biol Chem 2016, 291(10):5439-51. (Pub Med

Levels of GDF11 and GDF8 Decline With Age
Poggioli, T.; Vujic, A.; Yang, P.; Macias-Trevino, C.; Uygur, A.; Loffredo, F.S.; Pancoast, J.R.; Cho, M.; Goldstein, J.; Tandias, R.M.; Gonzalez, E.; Walker, R.G.; Thompson, T.B.; Wagers, A.J.; Fong, Y.W.; Lee, R.T., Circulating Growth Differentiation Factor 11/8 Levels Decline with Age. Circ Res. 2016, 118(1):29-37. (Pub Med)

Myostatin Attenuation Reduces Adiposity, but Activates Adipogenesis.
Li, N.; Yang, Q.; Walker, R.G.; Thompson, T.B,; Du, M.; Rodgers, B.D., Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis. Endocrinology 2016, 157(1):282-91. (Pub med)


Patent Evaluation of Myostatin Binding Proteins.
Walker, R.G.; Thompson, T.B., Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344. Expert Opin Ther Pat. 2015, 25(5), 619-24. (Pub Med)

Biochemistry and Biology of GDF11 and Myostatin.
Walker, R.G.; Poggioli, T.; Katsimpardi, L.; Buchanan, S.M.; Oh, J.; Wattrus, S.; Heidecker, B.; Fong, Y.W.; Rubin, L.L.; Ganz, P.; Thompson, T.B.; Wagers, A.J.; Lee, R.T., Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation. Circ Res. 2016, 118(7):1125-41. (Pub Med

Patent Evaluation of Myostatin Binding Proteins.
Walker, R.G.; Thompson, T.B., Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344. Expert Opin Ther Pat. 2015, 25(5), 619-24. (Pub Med)

Patent Evaluation of Myostatin Binding Proteins.
Walker, R.G.; Thompson, T.B., Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344. Expert Opin Ther Pat 2015, 25(5), 619-24. (Pub Med)

Alternate Binding Modes for GASP-mediated Inhibition of Myostatin.
Walker, R.G.; Angerman, E.B.; Kattamuri, C.; Lee, Y.S.; Lee, S.J.; Thompson, T.B., Alternative binding modes identified for growth and differentiation factor-associated serum protein (GASP) family antagonism of myostatin. J Biol Chem 2015, 290(12), 7506-16. (Pub Med)

Role of Conserved Prolines in Apolipoprotein A-IV Structure and Function.
Deng, X.; Walker, R.G.; Morris, J.; Davidson, W.S.; Thompson, T.B., Role of conserved proline residues in human apolipoprotein A-IV structure and function. J Biol Chem 2015, 25(5):619-24. (Pub Med)

Structure of NBL1.
Nolan, K.; Kattamuri, C.; Luedeke, D.M.; Angerman, E.B.; Rankin, S.A.; Stevens, M.L.; Zorn, A.M.; Thompson, T.B., Structure of neuroblastoman suppressor of tumorigenicity 1 (NBL1): insights for the functional variability across bone morphogenetic protein (BMP) antagonists. J Biol Chem 2015, 290(8), 4759-71. (Pub Med)


Amino Acid 72 Alters Activity of GDF9 Homodimers.
Peng, J.; Wigglesworth, K.; Rangarajan, A.; Eppig, J.J.; Thompson, T.B.; Matzuk, M.M., Amino acid 72 of mouse and human GDF9 mature domain is responsible for altered homodimer bioactivities but has subtle effects on GDF9:BMP15 heterodimer activities. Biol Reprod 2014, 91(6), 142. (Pub Med)

DAN-family Review.
Nolan, K.; Thompson, T.B., The DAN family: modulators of TGFß signaling and beyond. Protein Sci 2014, 23(8), 999-1012. (Pub Med)

Myostatin Stimulates C2C12 Myoblast Proliferation.
Rodgers, B.D.; Wiedeback, B.D.; Hoversten, K.E.; Jackson, M.F.; Walker, R.G.; Thompson, T.B., Myostatin stimulates, not inhibits, C2C12 myoblast proliferation. Endocrinology 2014, 155(3), 670-5. (Pub Med)

Structure of Apolipoprotein A-IV Determined by Cross-linking, Molecular Dynamics, and SAXS
Walker, R.G.; Deng, X.; Melchior, J.T.; Morris, J.; Tso, P.; Jones, M.K.; Segrest, J.P.; Thompson, T.B.; Davidson, W.S., The structure of human apolipoprotein A-IV as revealed by stable isotope-assisted cross-linking, molecular dynamics, and small angle x-ray scattering. J Biol Chem 2014, 289(9), 5596-608. (Pub Med)


Small Molecule Screening for Inhibitors of Myostatin and Activin A.
Cash, J.N.; Angerman, E.B.; Keutmann, H.T.; Thompson, T.B., Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A. J Biomol Screen 2013, 18(7), 837-44. (Pub Med)

SAXS of Apolipoprotein A-IV Reveals Importance of Termini.
Deng X.; Morris J.; Chaton, C.; Schroder, G.F.; Davidson, W.S.; Thompson T.B., Small-angle X-ray scattering of apolipoprotein A-IV reveals the importance of its termini for structural stability.J Biol Chem 2013, 288(7), 4854-66. (Pub Med)

Activins Signal via BMPR2 in Gonadotrope-like Cells.
Rejon C.A..; Hancock, M.A.; Li, Y.N.; Thompson, T.B.; Hebert, T.E.; Bernard, D.J., Activins bind and signal via bone morphogenetic protein receptor type II (BMPR2) in immortalized gonadotrope-like cells. Cell Signal 2013, 25(12), 2717-26. (Pub Med)

Structure of Protein Related to Dan and Cerberus (PRDC).
Nolan, K.; Kattamuri, C.; Luedeke, D.M.; Jagpal, A.; Zhang, F.; Linhardt, R.; Kenny, A.P.; Zorn, A.M.; Thompson, T.B., Structure of protein related to dan and cerberus: insights into the mechanism of bone morphogenetic protein antagonism. Structure 2013, 21(8), 1417-29. (Pub Med) PDB: 4JPH


DAN Family Antagonists Exist as Noncovalent Dimers.
Kattamuri, C.; Luedeke, D.M.; Nolan, K.; Rankin, S.A.; Greis, A.; Zorn, A.M.; Thompson, T.B., Members of the dan family are BMP antagonists that form highly stable noncovalent dimers. J Mol Bio 2012, 424(5), 313-27. (Pub Med)

Analysis of Heparin-Follistatin Binding and Interactions.
Zhang, F.; Beaudet, J.M.; Luedeke, D.M.; Walker, R.G.; Thompson, T.B.; Linhardt, R.J., Analysis of the interaction between heparin and follistatin and heparin and follistatin-ligand complexes using surface plasmon resonance. Biochemistry 2012, 51(34), 6797-803. (Pub Med)

Contribution of Follistatin's Domains towards Antagonism.
Cash, J.N.; Angerman, E.B.; Keutmann, H.T.; Thompson, T.B., Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism. Mol Endocrinol 2012, 26(7), 1167-78.

Structure of Apolipoprotein A-IV.
Deng, X.; Morris, J.; Dressmen, J.; Tubb, M.R.; Tso, P.; Jerome, W.G.; Davidson, W.S.; Thompson, T. B., The structure of dimeric apolipoprotein A-IV and its mechanism of self-association. Structure 2012, 20(5), 767-79. (Pub Med) PDB: 3S84

Dehydration and Diffraction of Apolipoprotein A-IV Crystals.
Deng X.; Davidson W.S.; Thompson, T.B., Improving the diffraction of apoA-IV crystals through extreme dehydration.Acta Crystallogr Sect F Struct Biol Cryst Commun 2012, 68(Pt 1), 105-10. (Pub Med)

Purification of PRDC.
Kattamuri, C.; Luedeke, D.M.; Thompson, T.B., Expression and purification of recombinant protein related to DAN and cerberus (PRDC). Protein Expr Purif 2012, 82(2), 389-95. (Pub Med)

Myostatin in Complex with FSTL3.
Cash, J.N.; Angerman, E.B.; Kattamuri, C.; Nolan, K.; Zhao, H.; Sidis, Y.; Keutmann, H.T.; Thompson, T. B., Structure of myostatin:follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding. J Biol Chem 2012, 287(2), 1043-53. (Pub Med) PDB: 3SEK

Previous Work

Myostatin in Complex with FST288.
Cash, J.N.; Rejon, C.A.; McPherron, A.C.; Bernard, D.J.; Thompson, T. B., The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. Embo J 2009, 28(17), 2662-76. (Pub Med) PDB: 3HH2

Activin in Complex with FSTL3.
Stamler, R.; Keutmann, H. T.; Sidis, Y.; Kattamuri, C.; Schneyer, A.; Thompson, T. B., The structure of FSTL3:activin a complex: differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem 2008, 283(47), 32831-8. (Pub Med) PDB: 3B4V

Activin in Complex with FST288 (Northwestern University).
Thompson, T. B.; Lerch, T. F.; Cook, R. W.; Woodruff, T. K.; Jardetzky, T. S., The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 2005, 9(4), 535-43. (Pub Med)  PDB: 2B0U